Close
FINDING CURES TOGETHER<sup>SM</sup>

Hematologic Malignancies: Translating Discoveries to Novel Therapies

​May 6-9, 2017
Westin Boston Waterfront
Boston, Massachusetts

Extended Abstract Submission and Award Application Deadline: Thursday, March 9, 2017
Extended Advance Registration Deadline: Thursday, March 30, 2017

Conference Chair:
Jonathan D. Licht, University of Florida Health Cancer Center, Gainesville, Florida

Conference Cochairs:
Lucy A. Godley, University of Chicago, Chicago, Illinois
Louis M. Staudt, National Cancer Institute, Bethesda, Maryland
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts

Scientific Program Committee
Julian Adams, Infinity Pharmaceuticals, Inc., Boston, Massachusetts
Rajesh Chopra, The Institute Of Cancer Research, London, England
Carlo M. Croce, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Riccardo Dalla-Favera, Columbia University Institute for Cancer Genetics, New York, New York
Faith E. Davies, University of Arkansas for Medical Sciences, Little Rock, Arkansas
John E. Dick, University of Toronto, Toronto, Ontario, Canada
Adolfo Ferrando, Columbia University, New York, New York
Catriona H. M. Jamieson, UCSD Moores Cancer Center, La Jolla, California
Ricky W. Johnstone, Peter MacCallum Cancer Center, Melbourne, Australia
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, New York
Mignon L. Loh, University of California, San Francisco, San Francisco, California
Ravindra Majeti, Stanford University, Stanford, California
Ari M. Melnick, Weill Cornell Medical College, New York, New York
Stanley R. Riddell, Fred Hutchinson Cancer Research Center, Seattle, Washington
Veronika Sexl, VetmedUni, Institute of Pharmacology and Toxicology, Vienna, Austria
Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
Rodger E. Tiedemann, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Join us for the Second AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies! This conference will include presentations pertaining to leukemia, lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms, spanning the spectrum of cancer science and medicine, from basic science discoveries to their translation in the clinic. Plenary sessions will be centered on scientific topics relevant to all blood cancers, such as genomics, epigenetics, cell death pathways, the tumor microenvironment, and chemical biology, as well as translational and clinical topics such as resistance and response to therapy, immunotherapy, and more.

This conference offers a unique opportunity for a lively discussion, in a small setting, of the challenges in the field among basic, translational, and clinical researchers, and for potential collaborations between national and international investigators.

There will be ample opportunities for networking, both with colleagues over scientific topics and with the stellar roster of invited speakers. Additionally, short talks from submitted abstracts will be selected for inclusion in the plenary sessions.

Make plans to join us this May in Boston for a program that will be appealing and of collaborative and educational benefit for scientists and clinicians studying any of the hematologic malignancies!

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available


#AACRheme17